Table 3. Results of Cox proportional hazards model for OS and AML progression excluding patients who died in the first 6 months (landmark analysis) and including all patients.
| Model factors | Hazard ratio (95% CI) | P-value |
|---|---|---|
| 6-Month landmark analysis: OS (N=132) | ||
| Age, years | 1.05 (1.03–1.08) | <0.001 |
| Sex (male vs female) | 1.95 (1.16–3.28) | 0.012 |
| del(5q) (plus ⩾1 abnormality vs isolated) | 1.65 (0.97–2.81) | 0.065 |
| Bone marrow blasts (⩾5% vs <5%) | 2.03 (1.15–3.58) | 0.015 |
| Platelet count, × 109/l | 1.00 (0.99–1.00) | 0.030 |
| Absolute neutrophil count, × 109/l | 1.14 (0.97–1.34) | 0.119 |
| Minimum hemoglobin level,a g/dl | 0.78 (0.63–0.98) | 0.035 |
| RBC-TI ⩾8 weeks (time dependent) | 0.27 (0.16–0.46) | <0.001 |
| 6-Month landmark analysis: AML progression (N=131)b | ||
| Time since diagnosis, years | 0.89 (0.76–1.04) | 0.129 |
| Number of cytopenias (2 or 3 vs 1) | 2.82 (1.10–7.27) | 0.031 |
| IPSS risk score (High, Int-2, Int-1 vs Low)c | 5.29 (1.82–15.41) | 0.002 |
| RBC-TI ⩾8 weeks (time dependent) | 0.44 (0.17–1.10) | 0.080 |
| Overall population: OS (N=148) | ||
| Age, years | 1.05 (1.03–1.08) | <0.001 |
| Sex (male vs female) | 1.75 (1.07–2.89) | 0.027 |
| FAB (RAEB or CMML vs RA or RARS) | 1.95 (1.18–3.20) | 0.009 |
| Platelet count, × 109/l | 1.00 (0.99–1.00) | 0.124 |
| Absolute neutrophil count, × 109/l | 1.12 (1.00–1.31) | 0.150 |
| Minimum hemoglobin level,a g/dl | 0.81 (0.66–0.99) | 0.044 |
| RBC-TI ⩾8 weeks (time dependent) | 0.30 (0.18–0.49) | <0.001 |
| Overall population: AML progression (N=147)b | ||
| del(5q) (plus ⩾1 abnormality vs isolated) | 3.25 (1.46–7.23) | 0.004 |
| RBC-TI ⩾8 weeks (time dependent) | 0.48 (0.21–1.10) | 0.083 |
Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; del(5q), chromosome 5q deletion; FAB, French–American–British; Int, intermediate; IPSS, International Prognostic Scoring System; OS, overall survival; RA, refractory anemia; RAEB, RA with excess blasts; RARS, RA with ringed sideroblasts; RBC-TI, red blood cell-transfusion independence.
Notes: Patients without a death date were censored at last known date of being alive. Only factors with P<0.15 are presented.
a
Minimum hemoglobin concentration in the 8-week baseline period.
b
One patient was diagnosed with AML at baseline and therefore excluded from the analysis.
c
Most patients had Low or Intermediate-1 risk IPSS (33.1 and 46.6%, respectively).